Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year
Asha Therapeutics Selected as a BLUE KNIGHT™ Company by Johnson & Johnson Innovation and BARDA
Inside the Innovation Arena – A Recap of Our BLUE KNIGHT™ QuickPitch: Activating for the Future
Asha TX to present breakthrough data for ASHA-044 tareting Beta-Catenin in colorectal cancer at NGIO
Targeting mitochondria in ME/CFS and Long Haul COVID with ASHA-091
Asha Therapeutics Announces the Presentation of New Data on ASHA-1007, a Novel VHL Recruiter for TPD